Journal of Antimicrobial Chemotherapy (2003) 51, 37-42
© 2003 The British Society for Antimicrobial Chemotherapy
Supplement |
Maximizing efficacy and reducing the emergence of resistance
Department of Medical Microbiology, City Hospital, Birmingham B18 7QH, UK
Abstract
An understanding of the pharmacokinetic and pharmacodynamic properties of antimicrobial agents enables better choices to be made in the clinical situation. The fluoroquinolones share several useful pharmacokinetic properties, such as good bioavailability (in most cases >85%) and the ability to penetrate and concentrate intracellularly, giving them activity against pathogens such as Legionella pneumophila and Listeria monocytogenes. Nevertheless, there are some important differences between the fluoroquinolones, and even the newer fluoroquinolones demonstrate a range of pharmacodynamic properties. When considering the area under the inhibition curve (AUIC) and the Cmax/MIC, the comparative figures are: ciprofloxacin and ofloxacin (5–25, 1–5); levofloxacin, grepafloxacin and gatifloxacin (25–75, 5–10); trovafloxacin (75–250, 10–20) and moxifloxacin, clinafloxacin and gemifloxacin (>250, >20). The development of resistance is also a concern, and selecting an agent that reaches an adequate concentration above the MIC will reduce the opportunity for resistance to develop. These properties should be considered when selecting a fluoroquinolone either for inclusion in a formulary, or for use in an individual patient.
Footnotes
* Tel: +44-121-507-4254; Fax: +44-121-551-7763; E-mail: r.wise{at}bham.ac.uk
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  P. Spigaglia, F. Barbanti, T. Louie, F. Barbut, and P. Mastrantonio Molecular Analysis of the gyrA and gyrB Quinolone Resistance-Determining Regions of Fluoroquinolone-Resistant Clostridium difficile Mutants Selected In Vitro Antimicrob. Agents Chemother., June 1, 2009; 53(6): 2463 - 2468. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. T. M. Fascia, A. Singanayagam, and J. F. Keating Methicillin-resistant Staphylococcus aureus in orthopaedic trauma: IDENTIFICATION OF RISK FACTORS AS A STRATEGY FOR CONTROL OF INFECTION J Bone Joint Surg Br, February 1, 2009; 91-B(2): 249 - 252. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Grayo, M.-C. Lott-Desroches, O. Dussurget, R. Respaud, A. Fontanet, O. Join-Lambert, E. Singlas, and A. Le Monnier Rapid Eradication of Listeria monocytogenes by Moxifloxacin in a Murine Model of Central Nervous System Listeriosis Antimicrob. Agents Chemother., September 1, 2008; 52(9): 3210 - 3215. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Haritova, N. V. Rusenova, P. R. Parvanov, L. D. Lashev, and J. Fink-Gremmels Integration of Pharmacokinetic and Pharmacodynamic Indices of Marbofloxacin in Turkeys Antimicrob. Agents Chemother., November 1, 2006; 50(11): 3779 - 3785. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. A. J. M. Bakker-Woudenberg, M. T. ten Kate, W. H. F. Goessens, and J. W. Mouton Effect of Treatment Duration on Pharmacokinetic/Pharmacodynamic Indices Correlating with Therapeutic Efficacy of Ceftazidime in Experimental Klebsiella pneumoniae Lung Infection. Antimicrob. Agents Chemother., September 1, 2006; 50(9): 2919 - 2925. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Roche, D. Fitzgerald, A. O'Rourke, and J. P. McCabe Methicillin-resistant Staphylococcus aureus in an Irish orthopaedic centre: A FIVE-YEAR ANALYSIS J Bone Joint Surg Br, June 1, 2006; 88-B(6): 807 - 811. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. V. Giannoudis, J. Parker, and M. H. Wilcox Methicillin-resistant Staphylococcus aureus in trauma and orthopaedic practice J Bone Joint Surg Br, June 1, 2005; 87-B(6): 749 - 754. [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Rodriguez, L. Cebrian, M. Lopez, M. Ruiz, I. Jimenez, and G. Royo Mutant prevention concentration: comparison of fluoroquinolones and linezolid with Mycobacterium tuberculosis J. Antimicrob. Chemother., March 1, 2004; 53(3): 441 - 444. [Abstract] [Full Text] [PDF]
|
|